AR089122A1 - Formulaciones orales para tratar la sobrecarga de metales - Google Patents

Formulaciones orales para tratar la sobrecarga de metales

Info

Publication number
AR089122A1
AR089122A1 ARP120104611A ARP120104611A AR089122A1 AR 089122 A1 AR089122 A1 AR 089122A1 AR P120104611 A ARP120104611 A AR P120104611A AR P120104611 A ARP120104611 A AR P120104611A AR 089122 A1 AR089122 A1 AR 089122A1
Authority
AR
Argentina
Prior art keywords
hydroxy
integer
hydrogen
independently selected
alkoxy
Prior art date
Application number
ARP120104611A
Other languages
English (en)
Spanish (es)
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of AR089122A1 publication Critical patent/AR089122A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP120104611A 2011-12-09 2012-12-07 Formulaciones orales para tratar la sobrecarga de metales AR089122A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568890P 2011-12-09 2011-12-09
US201161568914P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
AR089122A1 true AR089122A1 (es) 2014-07-30

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104611A AR089122A1 (es) 2011-12-09 2012-12-07 Formulaciones orales para tratar la sobrecarga de metales

Country Status (9)

Country Link
US (1) US8993606B2 (OSRAM)
EP (1) EP2787994A4 (OSRAM)
JP (1) JP2015500294A (OSRAM)
AR (1) AR089122A1 (OSRAM)
AU (1) AU2012347595A1 (OSRAM)
BR (1) BR112014013985A2 (OSRAM)
CA (1) CA2857990A1 (OSRAM)
TW (1) TW201338777A (OSRAM)
WO (1) WO2013086312A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 4’−デスフェリチオシン類似体の使用
CA2905026A1 (en) 2013-03-15 2014-09-18 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
EP3071201A4 (en) * 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
CN107708693A (zh) 2015-04-27 2018-02-16 佛罗里达大学研究基金会 代谢程序化的金属螯合剂及其用途
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
CN114302882A (zh) * 2019-07-19 2022-04-08 威佛(国际)股份公司 用于治疗输血依赖型β-地中海贫血(tdt)的膜铁转运蛋白抑制剂
JP2024504349A (ja) 2021-01-20 2024-01-31 ビフォー (インターナショナル) エージー 骨髄異形成症候群(mds)の処置において使用するためのフェロポーチン阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
BRPI0809077A2 (pt) 2007-03-15 2014-09-09 Univ Florida Res Foudantion Inc Análogos de poliéter de desferritiocina
WO2010009120A2 (en) * 2008-07-14 2010-01-21 Ferrokin Biosciences, Inc. Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011017054A2 (en) 2009-07-27 2011-02-10 Ferrokin Biosciences, Inc. Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
US20120184586A1 (en) 2009-08-25 2012-07-19 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
AU2011248158A1 (en) 2010-05-04 2012-12-20 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
EP2787994A1 (en) 2014-10-15
AU2012347595A1 (en) 2014-06-26
US20130225645A1 (en) 2013-08-29
WO2013086312A1 (en) 2013-06-13
BR112014013985A2 (pt) 2017-06-13
TW201338777A (zh) 2013-10-01
EP2787994A4 (en) 2015-08-26
JP2015500294A (ja) 2015-01-05
US8993606B2 (en) 2015-03-31
CA2857990A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
CO2018013717A2 (es) Piridinas sustituidas como inhibidores de dnmt1
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CO6541528A2 (es) Derivados de la cromenona
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY36124A (es) Derivados de carboxamida
CU20190042A7 (es) Compuestos derivados de naftiridinona
UY36123A (es) Derivados de carboxamida
UY33019A (es) Nuevos derivados de 2-aminotiadiazol
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal